Sage Therapeutics to Webcast R&D Day on December 13, 2016
December 07 2016 - 7:00AM
Business Wire
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage
biopharmaceutical company developing novel medicines to treat
life-altering central nervous system (CNS) disorders, today
announced that it will webcast its R&D Day on Tuesday, December
13, 2016 from 12:30 p.m. to 3:30 p.m. ET in Boston, MA.
The event will highlight Sage’s R&D strategy, translational
approaches and clinical development plans for SAGE-547 in
super-refractory status epilepticus and postpartum depression, and
for SAGE-217 in both mood and movement disorders.
In addition to presentations from members of the Sage management
team, guest speakers include:
- Eric Rosenthal, M.D., Associate
Director, Neurosciences Intensive Care Unit; Director,
Neurocritical Care Fellowship Program and Director, Critical Care
Neuromonitoring at Massachusetts General Hospital
- Samantha Meltzer-Brody, M.D., M.P.H.,
Associate Professor; Associate Chair for Faculty Development; and
Director, Perinatal Psychiatry Program, University of North
Carolina Center for Women's Mood Disorders
A live webcast of the presentations can be accessed on the
investor page of Sage's website at investor.sagerx.com. A
replay of the webcast will also be archived for up to 30 days on
Sage's website following the conference. A scientific poster
exhibit will take place at 3:30 p.m. ET and will not be
webcast.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical
company committed to developing novel medicines to transform the
lives of patients with life-altering central nervous system (CNS)
disorders. Sage has a portfolio of novel product candidates
targeting critical CNS receptor systems, GABA and NMDA. Sage's lead
compound, SAGE-547, is in Phase 3 clinical development for
super-refractory status epilepticus, a rare and severe seizure
disorder, and for postpartum depression. Sage is developing its
next generation modulators, including SAGE-217 and SAGE-718, with a
focus on acute and chronic CNS disorders.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161207005247/en/
Investor Contact:Sage TherapeuticsPaul Cox,
617-299-8377paul.cox@sagerx.comorMedia Contact:Suda
Communications LLCMaureen L. Suda,
585-387-9248maureen.suda@sagerx.com
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Apr 2023 to Apr 2024